title: Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer.
abstract: Until now, no molecular parameter has been available for predicting the metastatic potential of prostate tumours, which leaves their outcome uncertain despite an apparent benign histology or early stage. Abnormal expression of adhesion molecules, such as E-cadherin, can be contributing factors for increased invasiveness and metastatic potential. Histological analysis for E-cadherin expression was carried out on paraffin-embedded tumour tissues. Tumour metastatic potential was indirectly evaluated by detecting circulating prostate cells (CPC), using reverse transciptase-polymerase chain reaction (RT-PCR) and prostate-specific membrane antigen (PSMA) as a target. Patients were followed-up for a median of 14 months (range 10--19 months) after surgery with serum prostate-specific antigen (PSA) level measurement. Interestingly, 23 of 44 localised tumours exhibited aberrant E-cadherin expression. Prior to primary surgery, PSMA RT-PCR detected the spread of prostate cells to the blood in 24 patients. Statistical analysis showed that abnormal E-cadherin expression in the tumours was the only variable that was independently correlated with prostate cell dissemination in the blood (P<0.0001). In logistic regression analysis, abnormal E-cadherin expression was a significant independent predictor for a later biological relapse. This impaired adhesion status was clearly correlated with a haematogenous spread of the primary tumour cells. It could therefore be an objective way to restrict the indications for radical surgery to patients not presenting with this feature.
authors.affiliation: Biochemistry A Laboratory, Saint-Antoine AP-HP University Hospital, 184 ru du Faubourg, Saint-Antoine, 75012 Paris, France. slyvain.loric@sat.ap-hop-paris.fr
authors.forename: S
authors.initials: S
authors.lastname: Loric
authors.forename: V
authors.initials: V
authors.lastname: Paradis
authors.forename: J L
authors.initials: JL
authors.lastname: Gala
authors.forename: P
authors.initials: P
authors.lastname: Berteau
authors.forename: P
authors.initials: P
authors.lastname: Bedossa
authors.forename: G
authors.initials: G
authors.lastname: Benoit
authors.forename: P
authors.initials: P
authors.lastname: Eschwège
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000954:Antigens, Surface; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015820:Cadherins / Q000378:metabolism*; D002268:Carboxypeptidases / Q000097:blood; D005500:Follow-Up Studies; D043425:Glutamate Carboxypeptidase II; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000378:metabolism; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology*; D012008:Recurrence; D012044:Regression Analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000954:Antigens, Surface; D014408:Biomarkers, Tumor; D015820:Cadherins; D002268:Carboxypeptidases; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D017430:Prostate-Specific Antigen